FirstWord

If it successfully closes the offering, Lycia will be the fifth biotech to IPO this quarter.

The collaboration will explore use cases that could improve clinical-trial efficiency, including identifying eligible patients earlier and easier, across several disease areas.

RAP-219, a TARPγ8-specific AMPA receptor negative allosteric modulator, achieved the primary endpoint of a mid-stage study for the treatment of bipolar mania.

Emvistegrast, an α4β7 integrin inhibitor, met its primary endpoint in the Phase II SWIFT study in ulcerative colitis (UC).

The partners will use generative and predictive AI to refine the lipid components of drug-carrying nanoparticles, although specific disease targets have yet to be disclosed.

Palisade Bio Presents Rapid Endoscopic Improvement and New ...

THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ES...

CHARLESTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular...

Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo. CARSON CITY, Nev., Oct...

HER3‑targeted PET imaging demonstrated tumor uptake and retention, supporting ATNM‑400's potential to deliver sustained alpha radiation to tumors over a timeframe consistent with Actinium‑225's 10-day...